Economic evaluation of universal newborn hepatitis B vaccination in China

Vaccine

Volumn 31, Issue 14, 2013, Pages 1864-1869

  Lu, Sandy Qiuying ^a,b   McGhee, Sarah M ^a   Xie, Xu ^b   Cheng, Jinquan ^b   Fielding, Richard ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Cost effectiveness analysis; Hepatitis B virus; Vaccine

Indexed keywords

HEPATITIS B VACCINE;

ARTICLE; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE TRANSMISSION; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH PROGRAM; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; NEWBORN; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; VACCINATION;

EID: 84875250558     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.020     Document Type: Article

References (44)

1. Liu J., Fan D. Hepatitis B in China. Lancet 2007, 369:1582-1583.
2. WHO Publication Hepatitis B vaccines: WHO position paper - recommendations. Vaccine 2010, 28:589-590.
3. Zhou Y.H., Wu C., Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl) 2009, 122:98-102.
4. Liang X.F., Bi S.L., Yang W.Z., Wang L.D., Cui G., Cui F.Q., et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009, 200:39-47.
5. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001, 10:751-774.
6. Hung H.F., Chen T.H. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Vaccine 2009, 27:6770-6776.
7. Aggarwal R., Ghoshal U.C., Naik S.R. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 2003, 38:215-222.
8. Kim S.Y., Salomon J.A., Goldie S.J. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ 2007, 85:833-842.
9. Zhang S.X., Dang R.B., Zhang W.D., Liang X.F., Cui F.Q. Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China. Zhonghua Liu Xing Bing Xue Za Zhi 2008, 29:1003-1008.
10. Liu Z.G., Zhao S.J., Zhang Y.X. Cost-benefit analysis on immunization of newborns with hepatitis B vaccine in Jinan City. Zhonghua Liu Xing Bing Xue Za Zhi 1995, 16:81-84.
11. Dang R.B., Zhang S.X., Zhang W.D., Liang X.F., Cui F.Q., Zhao F. Assessment for immune effectiveness of hepatitis B vaccination among infant population in China. Chin J Public Health 2009, 25:385-387.
12. Wang L., Li H., Wang S.S., Gong J., Zeng X.J., Li R.C., et al. Studies on immunization strategies for hepatitis B in different endemic areas of China. Zhonghua Yu Fang Yi Xue Za Zhi 1999, 33:104-106.
13. Wu G.Y., Gong Y.L., Yu S.L., Zhao R.D., Qin H.J. Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi 2004, 25:474-478.
14. China Ministry of Health. Chinese Health Statistics Yearbook 2010 [cited 2012 April 20]; available from: http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2010/index2010.html.
15. Lin X.M., Robinson N.J., Thursz M., Rosenberg D.M., Weild A., Pimenta J.M., et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 2005, 20:833-843.
16. WHO Publication China life table 2008, [cited 2012 April 20]. Available from. http://apps.who.int/gho/data/%3Fvid=710.
17. Wang J.S., Zhu Q.R. A study on the efficacy of hepatitis B immunoglobulin combining with hepatitis B vaccine in interrupting the maternal-infantile transmission of hepatitis B virus. Chin J Pract Pediat 2000, 15:558-560.
18. Lee C., Gong Y., Broke J., Boxall E.H., Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006, CD004790.
19. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
20. Hu M., Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health 2009, 12(Suppl. 3):S89-S92.
21. Chen D., Yao G.B., Chen W. Economic evaluation of peginterferon α-2a and lamivudine in the treatment of HBeAg-positive chronic hepatitis B. Chin J Infect Dis 2007, 25(8).
22. Liang S., Zhang S.X., Ma Q.S., Xiao H.W., Lu Q.Y., Xie X., et al. Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China. Zhonghua Liu Xing Bing Xue Za Zhi 2010, 31:1340-1345.
23. Lam E.T., et al. Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes 2009, 7:52.
24. Lam C.L., Wong C.K., Lam E.T., Lo Y.Y., Huang W.W. Population norm of Chinese (HK) SF-12 health survey_version 2 of Chinese adults in Hong Kong. HK Pract 2010, 32:77-86.
25. Zhao F.L., Yue M., Yang H., Wang T., Wu J.H., Li S.C. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients. Value Health 2010, 13:649-656.
26. WHO Publication WHO guide for standardization of economic evaluations of immunization programmes 2005, World Health Organization Press, Switzerland.
27. National Bureau of Statistics of China China National Economy and Social Development Statistical Yearbook 2003 2003, [cited on 2012 April 20]. http://www.stats.gov.cn/tjgb/ndtjgb/qgndtjgb/t20040226_402131958.htm.
28. Liang X.F., Bi S.L., Yang W.Z., Wang L.D., Cui G., Cui F.Q., et al. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
29. Wang F.Z., Cui F.Q., Lu Y., Chen Y.S., Zhen W., Liang X.F. Analysis on reported hepatitis B cases on pilot surveillance in 18 counties of 8 provinces of China. China Immun 2007, 13:309-311.
30. Chen D., Yao G.B., Chen W. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol 2005, 34:132-137.
31. Marion S.A., Tomm Pastoreet M., Pi D.W., Mathias R.G. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 1994, 140:734-746.
32. Hutton D.W., So S.K., Brandeau M.L. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010, 51:405-414.
33. Zhang S., Li R.T., Wang Y.Y., Liu Q.L., Zhou Y.H., Hu Y.L. Seroprevalence of hepatitis B surface antigen among pregnant women in Jiangsu, China, 17 years after introduction of hepatitis B vaccine. Int J Gynaecol Obstet 2010, 109:194-197.
34. Edmunds W.J., Medley G.F., Nokes D.J., O'Callaghan C.J., Whittle H.C., Hall A.J. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996, 117:313-325.
35. Tassopoulos N.C., Papaevangelou G.J., Sjogren M.H., Roumeliotou-Karayannis A., Gerin J.L., Purcell R.H. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987, 92:1844-1850.
36. Karvountzis G.G., Redeker A.G., Peters R.L. Long term follow-up studies of patients surviving fulminant viral hepatitis. Gastroenterology 1974, 67:870-877.
37. Edmunds W.J., Medley G.F., Nokes D.J., Hall A.J., Whittle H.C. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993, 253:197-201.
38. Hong D.Q., Li J.S., Dai H.M. A follow-up study on 103 HBsAg carriers during 16-21 years. Zhonghua Yu Fang Yi Xue Za Zhi 1994, 28:287-290.
39. Wu G., Zhou W., Zhao Y., Guo S., Wang Z., Zou S., et al. Study on the natural history of chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2002, 10:46-48.
40. Ikeda K., Saitoh S., Koida I., Arase Y., Tsubota A., Chayama K., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993, 18:47-53.
41. Marcellin P., Castelnau C., Martinot-Peignoux M., Boyer N. Natural history of hepatitis B. Minerva Gastroenterol Dietol 2005, 51:63-75.
42. Hui A.Y., Chan H.L., Leuang N.W., Hung L.C., Chang F.K., Sung K.K. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. J Clin Gastroenterol 2002, 34:569-572.
43. Chen J.R., Sankaranarayanan R., Shen Z. Population-based cancer survival: an analysis of 16,922 cases. Zhonghua Zhong Liu Za Zhi 1998, 20:202-206.
44. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., Spiegel B.M. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005, 142:821-831.